Power morcellators: A review of current practice and assessment of risk

Sangeeta Senapati, Frank F. Tu, Javier F. Magrina

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Power morcellation has come under scrutiny because of a highly publicized case of disseminated leiomyosarcoma following a laparoscopic hysterectomy. A recent Federal and Drug Administration safety communication discouraging use of power morcellators on presumed uterine leiomyoma further highlights the need for reexamination of uterine tissue extraction. This clinical opinion aims to summarize current approaches to uterine/fibroid tissue extraction including the associated immediate and long-term potential risks of open power morcellation. The known data about risk of uterine sarcoma is reviewed followed by a discussion of acceptable risk and informed consent in the context of shared-decision making.

Original languageEnglish (US)
Pages (from-to)18-23
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume212
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Leiomyoma
Leiomyosarcoma
Informed Consent
Hysterectomy
Sarcoma
Decision Making
Communication
Safety
Pharmaceutical Preparations
Power (Psychology)
Morcellation

Keywords

  • hysterectomy
  • leiomyoma
  • morcellation
  • myomectomy
  • uterine malignancy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Power morcellators : A review of current practice and assessment of risk. / Senapati, Sangeeta; Tu, Frank F.; Magrina, Javier F.

In: American Journal of Obstetrics and Gynecology, Vol. 212, No. 1, 01.01.2015, p. 18-23.

Research output: Contribution to journalArticle

Senapati, Sangeeta ; Tu, Frank F. ; Magrina, Javier F. / Power morcellators : A review of current practice and assessment of risk. In: American Journal of Obstetrics and Gynecology. 2015 ; Vol. 212, No. 1. pp. 18-23.
@article{0e1c141e93cc47eab4f528d3f90a15fb,
title = "Power morcellators: A review of current practice and assessment of risk",
abstract = "Power morcellation has come under scrutiny because of a highly publicized case of disseminated leiomyosarcoma following a laparoscopic hysterectomy. A recent Federal and Drug Administration safety communication discouraging use of power morcellators on presumed uterine leiomyoma further highlights the need for reexamination of uterine tissue extraction. This clinical opinion aims to summarize current approaches to uterine/fibroid tissue extraction including the associated immediate and long-term potential risks of open power morcellation. The known data about risk of uterine sarcoma is reviewed followed by a discussion of acceptable risk and informed consent in the context of shared-decision making.",
keywords = "hysterectomy, leiomyoma, morcellation, myomectomy, uterine malignancy",
author = "Sangeeta Senapati and Tu, {Frank F.} and Magrina, {Javier F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ajog.2014.07.046",
language = "English (US)",
volume = "212",
pages = "18--23",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Power morcellators

T2 - A review of current practice and assessment of risk

AU - Senapati, Sangeeta

AU - Tu, Frank F.

AU - Magrina, Javier F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Power morcellation has come under scrutiny because of a highly publicized case of disseminated leiomyosarcoma following a laparoscopic hysterectomy. A recent Federal and Drug Administration safety communication discouraging use of power morcellators on presumed uterine leiomyoma further highlights the need for reexamination of uterine tissue extraction. This clinical opinion aims to summarize current approaches to uterine/fibroid tissue extraction including the associated immediate and long-term potential risks of open power morcellation. The known data about risk of uterine sarcoma is reviewed followed by a discussion of acceptable risk and informed consent in the context of shared-decision making.

AB - Power morcellation has come under scrutiny because of a highly publicized case of disseminated leiomyosarcoma following a laparoscopic hysterectomy. A recent Federal and Drug Administration safety communication discouraging use of power morcellators on presumed uterine leiomyoma further highlights the need for reexamination of uterine tissue extraction. This clinical opinion aims to summarize current approaches to uterine/fibroid tissue extraction including the associated immediate and long-term potential risks of open power morcellation. The known data about risk of uterine sarcoma is reviewed followed by a discussion of acceptable risk and informed consent in the context of shared-decision making.

KW - hysterectomy

KW - leiomyoma

KW - morcellation

KW - myomectomy

KW - uterine malignancy

UR - http://www.scopus.com/inward/record.url?scp=84919336584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919336584&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2014.07.046

DO - 10.1016/j.ajog.2014.07.046

M3 - Article

C2 - 25072737

AN - SCOPUS:84919336584

VL - 212

SP - 18

EP - 23

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -